Tuberc Respir Dis.  2017 Jan;80(1):93-94. 10.4046/trd.2017.80.1.93.

Is the Combination of ICS and LABA, a Therapeutic Option for COPD, Fading Away?

• Oh YM

• KMID: 2396347
• DOI: http://doi.org/10.4046/trd.2017.80.1.93

Abstract

No abstract available.

MeSH Terms

Pulmonary Disease, Chronic Obstructive*

Reference

1. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356:775–789.

2. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016; 374:2222–2234.

3. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008; 177:19–26.

4. Beeh KM. The role of bronchodilators in preventing exacerbations of chronic obstructive pulmonary disease. Tuberc Respir Dis. 2016; 79:241–247.

5. GOLD 2017 Global strategy for the diagnosis, management and prevention of COPD [Internet]. Global Initiative for Chronic Obstructive Lung Disease;2016. cited 2016 Dec 21. Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/.

6. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014; (3):CD010115.

7. Gershon AS, Campitelli MA, Croxford R, Stanbrook MB, To T, Upshur R, et al. Combination long-acting beta-agonists and inhaled corticosteroids compared with long-acting betaagonists alone in older adults with chronic obstructive pulmonary disease. JAMA. 2014; 312:1114–1121.